Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer

NCT06289062 PHASE2 RECRUITING

This multicenter, prospective clinical trial is designed to enroll PD-L1 expression-positive patients with stage IB1 cervical cancer who desire fertility preservation to undergo neoadjuvant chemotherapy in combination with a PD-1 inhibitor to evaluate the rate of complete pathologic remission, treatment-related adverse events, pregnancy rate, miscarriage rate, preterm birth rate, live birth rate, EFS and OS.

Details

Lead sponsor	Tongji Hospital
Phase	PHASE2
Status	RECRUITING
Enrolment	40
Start date	Wed May 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Dec 01 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Cervical Cancer
• Neoadjuvant Chemoimmunotherapy
• Fertility Preservation

Interventions

• Camrelizumab
• Cisplatin
• Nab paclitaxel
• biopsy

Countries

China